Display options
Cite
Nishimura Y, Sasagawa S, Ariyoshi M, et al. Systems pharmacology of adiposity reveals inhibition of EP300 as a common therapeutic mechanism of caloric restriction and resveratrol for obesity. Front Pharmacol. 2015;6:199doi: 10.3389/fphar.2015.00199.
Nishimura, Y., Sasagawa, S., Ariyoshi, M., Ichikawa, S., Shimada, Y., Kawaguchi, K., Kawase, R., Yamamoto, R., Uehara, T., Yanai, T., Takata, R., & Tanaka, T. (2015). Systems pharmacology of adiposity reveals inhibition of EP300 as a common therapeutic mechanism of caloric restriction and resveratrol for obesity. Frontiers in pharmacology, 6199. https://doi.org/10.3389/fphar.2015.00199
Nishimura, Yuhei, et al. "Systems pharmacology of adiposity reveals inhibition of EP300 as a common therapeutic mechanism of caloric restriction and resveratrol for obesity." Frontiers in pharmacology vol. 6 (2015): 199. doi: https://doi.org/10.3389/fphar.2015.00199
Nishimura Y, Sasagawa S, Ariyoshi M, Ichikawa S, Shimada Y, Kawaguchi K, Kawase R, Yamamoto R, Uehara T, Yanai T, Takata R, Tanaka T. Systems pharmacology of adiposity reveals inhibition of EP300 as a common therapeutic mechanism of caloric restriction and resveratrol for obesity. Front Pharmacol. 2015 Sep 15;6:199. doi: 10.3389/fphar.2015.00199. eCollection 2015. PMID: 26441656; PMCID: PMC4569862.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2015 Sep 15;6:199. doi: 10.3389/fphar.2015.00199. eCollection 2015.

Systems pharmacology of adiposity reveals inhibition of EP300 as a common therapeutic mechanism of caloric restriction and resveratrol for obesity.

Frontiers in pharmacology

Yuhei Nishimura, Shota Sasagawa, Michiko Ariyoshi, Sayuri Ichikawa, Yasuhito Shimada, Koki Kawaguchi, Reiko Kawase, Reiko Yamamoto, Takuma Uehara, Takaaki Yanai, Ryoji Takata, Toshio Tanaka

Affiliations

  1. Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine Tsu, Japan ; Mie University Medical Zebrafish Research Center Tsu, Japan ; Department of Systems Pharmacology, Mie University Graduate School of Medicine Tsu, Japan ; Department of Omics Medicine, Mie University Industrial Technology Innovation Institute Tsu, Japan ; Department of Bioinformatics, Mie University Life Science Research Center Tsu, Japan.
  2. Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine Tsu, Japan.
  3. Product Development Research Institute, Mercian Corporation Fujisawa, Japan.

PMID: 26441656 PMCID: PMC4569862 DOI: 10.3389/fphar.2015.00199

Abstract

Both caloric restriction (CR) and resveratrol (RSV) have beneficial effects on obesity. However, the biochemical pathways that mediate these beneficial effects might be complex and interconnected and have not been fully elucidated. To reveal the common therapeutic mechanism of CR and RSV, we performed a comparative transcriptome analysis of adipose tissues from diet-induced obese (DIO) zebrafish and obese humans. We identified nine genes in DIO zebrafish and seven genes in obese humans whose expressions were regulated by CR and RSV. Although the gene lists did not overlap except for one gene, the gene ontologies enriched in the gene lists were highly overlapped, and included genes involved in adipocyte differentiation, lipid storage and lipid metabolism. Bioinformatic analysis of cis-regulatory sequences of these genes revealed that their transcriptional regulators also overlapped, including EP300, HDAC2, CEBPB, CEBPD, FOXA1, and FOXA2. We also identified 15 and 46 genes that were dysregulated in the adipose tissue of DIO zebrafish and obese humans, respectively. Bioinformatics analysis identified EP300, HDAC2, and CEBPB as common transcriptional regulators for these genes. EP300 is a histone and lysyl acetyltransferase that modulates the function of histone and various proteins including CEBPB, CEBPD, FOXA1, and FOXA2. We demonstrated that adiposity in larval zebrafish was significantly reduced by C646, an inhibitor of EP300 that antagonizes acetyl-CoA. The reduction of adiposity by C646 was not significantly different from that induced by RSV or co-treatment of C646 and RSV. These results indicate that the inhibition of EP300 might be a common therapeutic mechanism between CR and RSV in adipose tissues of obese individuals.

Keywords: adipose tissue; caloric restriction; comparative transcriptome; ep300; obesity; resveratrol; systems pharmacology; zebrafish

References

  1. Biochem Biophys Res Commun. 2009 May 22;383(1):63-7 - PubMed
  2. Genes Dev. 2000 Apr 15;14(8):963-80 - PubMed
  3. Diabetologia. 2005 Sep;48(9):1776-83 - PubMed
  4. Ageing Res Rev. 2007 Aug;6(2):128-40 - PubMed
  5. FASEB J. 2005 Sep;19(11):1540-2 - PubMed
  6. Nat Rev Genet. 2006 Jan;7(1):55-65 - PubMed
  7. Biochim Biophys Acta. 2015 Jun;1852(6):1137-44 - PubMed
  8. Bioinformatics. 2003 Nov 1;19(16):2155-7 - PubMed
  9. PLoS Genet. 2012;8(8):e1002834 - PubMed
  10. Mol Cell. 2013 Jan 10;49(1):186-99 - PubMed
  11. Bioinformatics. 2006 Oct 15;22(20):2500-6 - PubMed
  12. Nucleic Acids Res. 2006 Jan 05;34(1):217-31 - PubMed
  13. Diabetes. 2014 Sep;63(9):2924-34 - PubMed
  14. J Biol Chem. 2007 Jan 5;282(1):151-8 - PubMed
  15. Genome Res. 2003 Nov;13(11):2498-504 - PubMed
  16. Cell Metab. 2011 Nov 2;14 (5):612-22 - PubMed
  17. Trends Cell Biol. 2012 Oct;22(10):546-54 - PubMed
  18. Chem Biol. 2010 May 28;17(5):471-82 - PubMed
  19. Oncogene. 2008 Jan 17;27(4):540-7 - PubMed
  20. Mol Cell. 2014 Mar 6;53(5):710-25 - PubMed
  21. Genes Dev. 2013 Oct 1;27(19):2072-85 - PubMed
  22. Biol Reprod. 2001 Aug;65(2):568-74 - PubMed
  23. Nucl Recept Signal. 2010 Nov 19;8:e005 - PubMed
  24. Bioinformatics. 2003 Jan 22;19(2):185-93 - PubMed
  25. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10412-7 - PubMed
  26. Int J Biol Sci. 2013 Sep 21;9(9):934-46 - PubMed
  27. Cell Mol Life Sci. 2013 Nov;70(21):3989-4008 - PubMed
  28. Zebrafish. 2011 Dec;8(4):203-10 - PubMed
  29. J Biol Chem. 2010 Jan 1;285(1):464-72 - PubMed
  30. J Biol Chem. 2013 Nov 22;288(47):33966-77 - PubMed
  31. Cell Metab. 2011 Aug 3;14 (2):219-30 - PubMed
  32. Int J Pediatr Obes. 2011 Jun;6(2-2):e360-3 - PubMed
  33. Cell Metab. 2013 Mar 5;17(3):411-22 - PubMed
  34. PLoS One. 2008 Jun 04;3(6):e2264 - PubMed
  35. Int J Obes (Lond). 2014 Mar;38(3):470-3 - PubMed
  36. J Clin Endocrinol Metab. 2013 Feb;98(2):E370-8 - PubMed
  37. Nucleic Acids Res. 2015 Apr 20;43(7):e47 - PubMed
  38. Biochem Pharmacol. 2009 Mar 15;77(6):1053-63 - PubMed
  39. J Clin Endocrinol Metab. 2007 Jun;92(6):2346-52 - PubMed
  40. Bioinformatics. 2006 Nov 15;22(22):2825-7 - PubMed
  41. PLoS Comput Biol. 2014 Jul 24;10(7):e1003731 - PubMed
  42. J Clin Endocrinol Metab. 2008 Jun;93(6):2027-34 - PubMed
  43. J Biol Chem. 2007 Jan 12;282(2):956-67 - PubMed
  44. J Biol Chem. 2011 Apr 1;286(13):11492-505 - PubMed
  45. Genes Dev. 2008 Jul 1;22(13):1753-7 - PubMed
  46. Environ Health Perspect. 2011 Mar;119(3):377-83 - PubMed
  47. Cell Cycle. 2011 Mar 15;10(6):904-11 - PubMed
  48. Cell Metab. 2009 Nov;10(5):392-404 - PubMed
  49. Bioinformatics. 2011 Nov 15;27(22):3209-10 - PubMed
  50. Biostatistics. 2007 Apr;8(2):485-99 - PubMed
  51. J Clin Invest. 2010 Dec;120(12):4316-31 - PubMed
  52. Food Chem Toxicol. 2009 Jun;47(6):1362-7 - PubMed
  53. Nature. 2004 Jun 17;429(6993):771-6 - PubMed
  54. Cell. 2006 Dec 15;127(6):1109-22 - PubMed
  55. Free Radic Biol Med. 2015 Nov;88(Pt B):381-90 - PubMed
  56. Science. 2004 Jul 16;305(5682):390-2 - PubMed
  57. Biochem Biophys Res Commun. 2009 Sep 11;387(1):13-8 - PubMed
  58. BMC Physiol. 2010 Oct 21;10:21 - PubMed

Publication Types